| Observation on the Efficacy of Aflibercept 8mg Intravitreal Injection Solution on Retinal Fluid in nAMD Patients With PED | Aflibercept | Phase 4 | Not yet recruiting | Honghua Yu,MD | Nov 17, 2026 |
| A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer | Bevacizumab | Phase 2 | Not yet recruiting | Korea University Anam Hospital | Nov 17, 2026 |
| Intensive Glycemic Control Combined With Brolucizumab for Diabetic Macular Edema | Brolucizumab | Not applicable | Not yet recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Nov 13, 2026 |
| Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors | Bevacizumab | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | Nov 12, 2026 |
| Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF Mutation | Bevacizumab | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | Nov 9, 2026 |
| Anti-VEGF Versus Prompt Laser or Observation for Proliferative Sickle Cell Retinopathy (ALPS) | Faricimab | Phase 3 | Not yet recruiting | University of Illinois Chicago | Nov 6, 2026 |
| Efficacy of Aflibercept With Sequential Laser Photocoagulation for Macular Edema Secondary to Retinal Artery Macroaneurysm. | Aflibercept | — | Not yet recruiting | New Valley University | Nov 6, 2026 |
| Circulating Tumor DNA Methylation-Guided Adjuvant Therapy Decision-Making in Patients With Resectable Colorectal Cancer Liver Metastases After Resection | Bevacizumab | Phase 2 | Recruiting | Fudan University | Nov 4, 2026 |
| A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer | Bevacizumab | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | Nov 4, 2026 |
| Novel endOvascular Therapy With beVAcizumab and Cannabinoids for Glioblastoma | Bevacizumab | Phase 1 | Not yet recruiting | Unity Health Toronto | Nov 2, 2026 |
| A Study of BON-C1393 in Adults With Advanced Solid Tumors | Bevacizumab | Phase 1 | Not yet recruiting | BeOne Medicines | Oct 29, 2026 |
| Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma | Bevacizumab | — | Not yet recruiting | Assiut University | Oct 29, 2026 |
| VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study | Aflibercept | Phase 2 | Not yet recruiting | University of Miami | Oct 23, 2026 |
| A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). | Aflibercept | Phase 3 | Recruiting | 4D Molecular Therapeutics | Oct 9, 2026 |
| Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP. | Ranibizumab | Phase 4 | Not yet recruiting | Southeast Retina Center, Georgia | Oct 7, 2026 |
| A Study to Compare GNR-139 and Eylea® in Patients With nAMD | Aflibercept | Phase 3 | Recruiting | AO GENERIUM | Sep 28, 2026 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02) | Aflibercept | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | Sep 25, 2026 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03) | Aflibercept | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | Sep 25, 2026 |
| Changes in Intraocular Pressure After Intravitreal Injection | Ranibizumab | — | Not yet recruiting | Assiut University | Sep 17, 2026 |
| Blepharoptosis After Repeated Intravitreal Anti-VEGF Injections: A Prospective Study | Aflibercept, Ranibizumab | — | Recruiting | Abdulkadir Küçük | Sep 15, 2026 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05) | Ranibizumab | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | Sep 11, 2026 |
| South Asian Patients With Diabetic Macular Oedema Treated With Faricimab Assessing the Efficacy, Durability, and Safety (SEAFAR Study) | Faricimab | Phase 4 | Not yet recruiting | Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust | Aug 7, 2026 |
| LEAP Strategy for Neovascular Age-Related Macular Degeneration | Faricimab, Conbercept, Ranibizumab | Not applicable | Not yet recruiting | Chinese PLA General Hospital | Aug 4, 2026 |
| A Study on the Combination of Tongluo Huayu Formula in Treating RVO of Phlegm-Stasis Intertwinement Type: Based on the Mechanism of Systemic Metabolic Regulation Mediated by Gut Microbiota | Conbercept | Not applicable | Not yet recruiting | First Affiliated Hospital of Zhejiang University | Jul 22, 2026 |
| Incidence of Hypoxia During Intravitreal Anti-VEGF (Vascular Endothelial Growth Factor) Injections for Retinopathy of Prematurity (ROP) Under Topical Anesthesia | Ranibizumab | — | Recruiting | Minia University | Jul 14, 2026 |
| A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome | Faricimab | Phase 4 | Recruiting | Cincinnati Eye Institute, Southwest Ohio | Jul 10, 2026 |
| Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy | Ranibizumab | Phase 3 | Recruiting | SANGMYUNG innovation | Jul 10, 2026 |
| Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial | Faricimab | Phase 2 | Not yet recruiting | Singapore National Eye Centre | Jul 2, 2026 |
| Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD) | Faricimab | — | Not yet recruiting | Sun Yat-sen University | May 12, 2026 |
| Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab | Faricimab, Ranibizumab | Not applicable | Recruiting | Osijek University Hospital | Apr 9, 2026 |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy | Bevacizumab gamma | Phase 2 | Recruiting | National Cancer Institute (NCI) | Apr 1, 2026 |
| Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: Pain, Procedure Time, Patient Satisfaction, and Safety | Faricimab | Not applicable | Active, not recruiting | Jakkrit Juhong | Mar 18, 2026 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial | Bevacizumab gamma | Phase 2 | Recruiting | City of Hope Medical Center | Dec 17, 2025 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial | Bevacizumab gamma | Phase 3 | Recruiting | City of Hope Medical Center | Dec 9, 2025 |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | Bevacizumab gamma | Phase 3 | Recruiting | National Cancer Institute (NCI) | Sep 30, 2025 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | Bevacizumab gamma | Phase 3 | Recruiting | NRG Oncology | Sep 10, 2025 |
| Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment | Conbercept | Phase 4 | Recruiting | First Affiliated Hospital of Chongqing Medical University | Aug 21, 2025 |
| Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema | Conbercept | — | Active, not recruiting | Tianjin Medical University Eye Hospital | Aug 6, 2025 |
| Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns | Brolucizumab | Phase 3 | Recruiting | Belfast Health and Social Care Trust | May 22, 2025 |
| Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy | Conbercept | Not applicable | Recruiting | Wang Yusheng | Dec 5, 2024 |
| Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer | Bevacizumab gamma | Phase 1 | Recruiting | National Cancer Institute (NCI) | Nov 20, 2024 |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Bevacizumab gamma | Phase 3 | Recruiting | NRG Oncology | Aug 30, 2024 |
| External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer | Bevacizumab gamma | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | Aug 9, 2024 |
| Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema | Brolucizumab | Phase 4 | Active, not recruiting | Guangdong Provincial People's Hospital | Jul 12, 2024 |
| Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy | Conbercept | Phase 4 | Active, not recruiting | Shanghai Eye Disease Prevention and Treatment Center | Mar 12, 2024 |
| Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | Brolucizumab | Not applicable | Active, not recruiting | Berner Augenklinik | Jun 21, 2021 |